Fast-tracked tirzepatide is looking to join the diabetes-turned-obesity drug market. Additional options in the class could be a boon to patients, given the persisting semiglutide shortage.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
Fast-tracked tirzepatide is looking to join the diabetes-turned-obesity drug market. Additional options in the class could be a boon to patients, given the persisting semiglutide shortage.